Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
4.140
-0.160 (-3.72%)
At close: Apr 1, 2025, 4:00 PM
4.225
+0.085 (2.04%)
Pre-market: Apr 2, 2025, 7:24 AM EDT

Jasper Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-71.27-64.47-37.69-30.64-31.67
Upgrade
Depreciation & Amortization
1.371.110.980.38-
Upgrade
Loss (Gain) From Sale of Assets
0.01----
Upgrade
Stock-Based Compensation
6.625.214.091.051.21
Upgrade
Other Operating Activities
0.490.98-12.59-6.0910.9
Upgrade
Change in Accounts Receivable
-0.66-0.660.6-
Upgrade
Change in Accounts Payable
-0.122.38-2.152.940.36
Upgrade
Change in Other Net Operating Assets
0.32.062.17-1.920.94
Upgrade
Operating Cash Flow
-62.6-52.07-45.86-33.68-18.27
Upgrade
Capital Expenditures
-0.55-0.27-0.58-2.43-
Upgrade
Sale of Property, Plant & Equipment
0.02----
Upgrade
Investing Cash Flow
-0.53-0.27-0.58-2.43-
Upgrade
Issuance of Common Stock
47.88101.930.060.240.05
Upgrade
Repurchase of Common Stock
--0.96---
Upgrade
Other Financing Activities
---89.98-
Upgrade
Financing Cash Flow
47.88100.970.06100.9711.29
Upgrade
Net Cash Flow
-15.2548.64-46.3864.86-6.98
Upgrade
Free Cash Flow
-63.15-52.33-46.43-36.11-18.27
Upgrade
Free Cash Flow Per Share
-4.33-5.01-12.73-31.69-105.60
Upgrade
Levered Free Cash Flow
-39.59-30.35-29.17-22.8-10.54
Upgrade
Unlevered Free Cash Flow
-39.59-30.35-29.17-22.8-10.54
Upgrade
Change in Net Working Capital
-0.62-6.631.67-1.22-1.17
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q